The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®
- 398 Downloads
The study estimated the cost-effectiveness of risedronate compared to no treatment in UK women using the FRAX algorithm for fracture risk assessment. A Markov cohort model was used to estimate the cost-effectiveness. Risedronate was found cost-effective from the age of 65 years, assuming a willingness to pay for a QALY of £30,000.
The aim of this study was to assess the cost-effectiveness of risedronate for the prevention and treatment in a UK setting using the FRAX® algorithm for fracture risk assessment. A further aim was to establish intervention thresholds with risedronate treatment.
The cost-effectiveness of risedronate was compared to no treatment in post-menopausal women with clinical risk factors for fracture using a Markov cohort model populated with data relevant for the UK. The model incorporated the features of FRAX® (the WHO risk assessment tool). The analysis had a health care perspective and quality adjusted life years was used as the main outcome measure.
Treatment was cost-effective from the age of 65 years, assuming a willingness to pay for a QALY of £30,000. Treatment was also cost-effective at all ages in women who had previously sustained a fragility fracture or in women with a parental history of hip fracture with a bone mineral density set at the threshold of osteoporosis. At the £30,000 threshold value for a QALY, risedronate was on average found to cost-effective below the 10-year probability of a major osteoporotic fractures of 13.0%.
Risedronate is a cost-effective agent for the treatment of established osteoporosis (osteoporosis and a prior fragility fracture) in women from the age of 50 years and older and above 65 years in women with osteoporosis alone. The results support the treatment recommendations in recent UK guidelines for osteoporosis.
KeywordsCost-effectiveness Fractures FRAX Osteoporosis QALY
We are grateful to Alliance for Better Bone Health for their financial support of this study.
Conflicts of interest
JAK, FB, OS, EMcC, HJ and AO act as advisors to and have received funding from many pharmaceutical companies involved in marketing products for treatment of osteoporosis.
- 7.National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Society of Rheumatology, Society of Endocrinology, British Orthopaedic Association, Primary Care Rheumatology Society, Osteoporosis 2000 and Osteoporosis Dorset (2008) Osteoporosis: clinical guideline for prevention and treatmentGoogle Scholar
- 10.National Institute for Clinical Excellence (NICE) (2005) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London. www.nice.org.uk
- 11.National Institute for Clinical Excellence (NICE) (2007) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London. www.nice.org.uk
- 12.National Institute for Clinical Excellence (NICE) (2007). Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London. www.nice.org.uk
- 13.National Institute for Clinical Excellence (NICE) (2008). Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London. www.nice.org.uk
- 14.National Institute for Clinical Excellence (NICE) (2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London. www.nice.org.uk
- 15.Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046CrossRefPubMedGoogle Scholar
- 16.Guide to the methods of technology appraisal. http://www.nice.org.uk/page.aspx?o=201974. 2008-05-03
- 36.National Statistics Online. http://www.statistics.gov.uk/StatBase/Product.asp?vlnk=14459&Pos=&ColRank=1&Rank=422
- 39.Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91CrossRefPubMedGoogle Scholar
- 40.Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Jama 282:1344–1352CrossRefPubMedGoogle Scholar
- 45.Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Jama 296:2927–2938CrossRefPubMedGoogle Scholar
- 46.Lloyd-Jones M, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: a systematic review. NHS R & D HTA ScHARR, SheffieldGoogle Scholar
- 49.Stevenson M, Davis S, Kanis J (2006) The hospitalization costs and outpatient costs of fragility fractures. Women's Health Medicine 4:149–151Google Scholar
- 52.Zethraeus N, Borgström F, Ström O, Kanis J, Jönsson B (2006) What is the risk of institutionalization after hip fracture? Osteoporos Int 17(Suppl 2):60Google Scholar
- 53.McLellan A, Reid D, Forbes K, Reid R, Campbell C, Gregori A (1999) Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland. www.nhshealthquality.org/nhsqis/controller?p_service=Content.show&p_applic=CCC&pContentID=2755. 6th May 2007
- 57.World Health Organization Assessment of osteoporosis at the primary health care level (2008). www.who.int/chp/topics/rheumatic/en/index.html
- 58.Kanis J, behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UKGoogle Scholar
- 60.Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, LondonGoogle Scholar
- 61.Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management. Royal College of Physicians and Bone and Tooth Society of Great Britain, LondonGoogle Scholar
- 62.Royal College of Physicians, Bone and Tooth Society of Great Britain and National Osteoporosis Society Glucocorticoid-Induced Osteoporosis (2002) Guidelines on prevention and treatment. Royal College of Physicians, Bone and Tooth Society of Great Britain and National Osteoporosis Society Glucocorticoid-induced osteoporosis, LondonGoogle Scholar
- 63.European Community (1998) Report on osteoporosis in the European Community. EC, StrasbourgGoogle Scholar
- 67.Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton L, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536CrossRefPubMedGoogle Scholar